---
title: "Zepbound Cancer Risk Signal Review: The Clinical Evidence"
description: "Zepbound has a boxed warning for rodent thyroid tumors, but no causal link to human medullary thyroid cancer is established. Covers trial and screening."
url: https://healthrx.com/zepbound/cancer-risk-considerations
publisher: HealthRX.com
---


HealthRX.com

Boxed warning comes from rodent studies, not human cases

[Print or save as PDF](https://healthrx.com/printables/zepbound/cancer-risk-considerations?print=1)

Key numbers

- 20.9% Mean body-weight loss at 72 weeks on the 15 mg dose in SURMOUNT-1 adults, versus 3.1% on placebo Source: [nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038), as cited Jan 15, 2025
- 0.3% Acute pancreatitis rate across all tirzepatide arms in the SURMOUNT-1 trial Source: [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806), as cited Jan 15, 2025
- HR 0.35 Hazard ratio for gallbladder cancer with GLP-1 agonist use vs insulin in an observational study Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39141387/), as cited Jan 15, 2025
- 40% Share of all U.S. cancers diagnosed annually attributed to overweight and obesity (CDC estimate) Source: [cdc.gov](https://www.cdc.gov/cancer/risk-factors/obesity.html), as cited Jan 15, 2025

[See the public record for Tirzepatide](https://healthrx.com/data/tirzepatide)

HealthRX.com quick answer. Tirzepatide (Zepbound) carries an FDA boxed warning for rodent thyroid C-cell tumors, but no causal link to human medullary thyroid carcinoma has been established in clinical trials or post-marketing surveillance to date. For most patients without a personal or family history of MTC or MEN2, the current evidence does not indicate elevated cancer risk from treatment.

At a glance

- Boxed warning / FDA black-box warning for thyroid C-cell tumors seen in rodents at all tested doses
- Human relevance / GLP-1R expression on human C-cells is low; causal MTC link unconfirmed
- SURMOUNT-1 cancer events / no statistically significant difference vs. Placebo at 72 weeks
- Key contraindication / personal or family history of MTC or MEN2 syndrome
- Pancreatitis signal / FDA label flags risk; acute pancreatitis rates were low in SURMOUNT-1
- Post-marketing / FDA MedWatch and WHO VigiBase data under active pharmacovigilance review
- Baseline screening / calcitonin measurement recommended if clinical suspicion of MTC exists
- Trial population / SURMOUNT-1 enrolled 2,539 adults; 72-week follow-up
- Obesity-cancer link / obesity itself raises risk for 13 IARC-classified cancers; weight loss may reduce that background risk

## Why a Cancer Risk Review Matters for Tirzepatide

[Tirzepatide](https://healthrx.com/products/tirzepatide) is a dual GIP and GLP-1 receptor agonist approved by the FDA in May 2022 for [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm) ([Mounjaro](https://healthrx.com/mounjaro)) and in November 2023 for chronic weight management (Zepbound). In SURMOUNT-1 (N=2,539), the 15 mg dose produced a mean body-weight loss of 20.9% at 72 weeks versus 3.1% with placebo, making it the most effective approved pharmacotherapy for obesity to date [1].

That efficacy comes alongside a class-wide safety profile that includes a prominent FDA boxed warning. Clinicians and patients reviewing the label encounter the phrase "thyroid C-cell tumors" on the first page. Understanding exactly what that signal means, where it comes from, and what it does not mean requires separating rodent pharmacology from human oncology.

### The Regulatory History in Brief

The boxed warning for thyroid C-cell tumors applies to all approved [GLP-1 receptor agonists](https://healthrx.com/classes-glp1-receptor-agonists/class-overview-monograph), including semaglutide ([Ozempic](https://healthrx.com/glp-1/ozempic)/[Wegovy](https://healthrx.com/wegovy)), [liraglutide](https://healthrx.com/liraglutide-generic) (Victoza/[Saxenda](https://healthrx.com/saxenda)), [dulaglutide](https://healthrx.com/dulaglutide-trulicity) (Trulicity), and exenatide (Byetta/Bydureon). Tirzepatide received the same warning during its NDA review because the preclinical package showed dose-dependent C-cell hyperplasia and tumors in Sprague-Dawley rats [2].

### What "Signal" Actually Means

A [safety signal](https://healthrx.com/zepbound/safety-signals-fda) is not a confirmed risk. The FDA defines a signal as "information that arises from one or more sources suggesting a new potentially causal association, or a new aspect of a known association, between an intervention and an event." The thyroid finding in tirzepatide's preclinical program met that threshold for labeling purposes without meeting the threshold for confirmed human carcinogenicity.

---

## Rodent Thyroid Findings: The Source of the Boxed Warning

The preclinical data that drove the boxed warning come from two-year carcinogenicity studies in Sprague-Dawley rats. These animals are known to have high GLP-1 receptor (GLP-1R) expression on thyroid C-cells and are considered a sensitive model for C-cell neoplasia. Tirzepatide produced C-cell hyperplasia and adenomas at all dose levels tested, with malignant C-cell carcinomas at higher exposures [2].

### Why Rodent Data Do Not Directly Predict Human Risk

Several biological differences limit the translational relevance of these findings:

- **GLP-1R expression density.** Human thyroid C-cells express GLP-1R at substantially lower levels than rat C-cells. A 2011 analysis by Waser et al. Using receptor autoradiography found that GLP-1R density on human C-cells was low to undetectable in most samples, while rat C-cells showed high receptor density [3].
- **Species-specific C-cell proliferation.** Sprague-Dawley rats develop spontaneous C-cell hyperplasia at elevated background rates compared with humans. The FDA's own pharmacology review for liraglutide (the first GLP-1 agonist to receive this warning) concluded that the rat model may not be predictive of human risk due to these receptor and proliferative differences [4].
- **Calcitonin data in human trials.** Across the SURMOUNT program, mean serum calcitonin levels did not show a clinically meaningful rise in the tirzepatide arms relative to placebo. Calcitonin is the primary biomarker for C-cell proliferation and MTC.

### What the FDA Label Actually States

The FDA is not asserting causation; it is flagging an unresolved question that warrants ongoing surveillance.

---

## SURMOUNT-1: Cancer Adverse Events in the Primary Trial

SURMOUNT-1 was a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2022 [1]. It enrolled 2,539 adults with a BMI of 30 or higher (or 27 with at least one weight-related comorbidity) and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, over 72 weeks.

### Reported Neoplasms in the Trial

The supplementary safety tables from SURMOUNT-1 reported neoplasms as a combined adverse-event category. The incidence of malignant neoplasms was numerically similar between the tirzepatide arms and placebo, with no statistically significant difference at P<0.05 for any cancer subtype. The trial was not powered to detect rare cancer signals; 72 weeks is also too short a follow-up to capture most solid-tumor endpoints with statistical confidence.

No cases of medullary thyroid carcinoma were reported in SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, or SURMOUNT-4 [1][5].

### Limitations of Trial-Based Cancer Surveillance

A 72-week phase 3 trial with roughly 2,500 participants cannot rule out a small absolute increase in cancer risk. MTC has a low baseline incidence of approximately 0.57 cases per 100,000 person-years in the general U.S. Population according to SEER data from the National Cancer Institute. Detecting a doubling of that rate would require tens of thousands of patient-years of follow-up. Post-marketing registries and long-term extension studies are the appropriate tools for that question.

---

## The GLP-1 Class: Broader Epidemiological Evidence

Tirzepatide has been on the market for a shorter period than the older GLP-1 receptor agonists, so the longest-duration human safety data come from liraglutide and semaglutide.

### Liraglutide Thyroid Data

Liraglutide received FDA approval in 2010. A 2022 Danish registry study published in JAMA by Pasternak et al. (N=145,410 GLP-1 agonist users matched to non-users) found no statistically significant association between GLP-1 receptor agonist use and MTC over a median follow-up of 3.9 years (adjusted hazard ratio 1.46, 95% CI 0.60 to 3.58) [6]. The confidence interval is wide, which reflects the rarity of MTC rather than evidence of harm.

### Semaglutide Thyroid Data

The SUSTAIN and STEP programs for semaglutide, which collectively enrolled more than 20,000 patients, reported no confirmed MTC cases in either the subcutaneous or oral formulations [7]. The FDA's 2021 review of the semaglutide NDA for weight management (Wegovy) concluded that the available human data did not establish a causal relationship between semaglutide and MTC.

### Pancreatic Cancer Signal

A separate concern raised in early post-marketing literature for GLP-1 agonists was a potential signal for pancreatic ductal adenocarcinoma. The LEADER trial (N=9,340, median follow-up 3.8 years) and SUSTAIN-6 (N=3,297, 2-year follow-up) found no significant increase in pancreatic cancer rates with liraglutide or semaglutide versus comparators [8]. SURMOUNT-1 reported 4 total pancreatitis cases across all tirzepatide arms (0.3%) versus 0 in placebo, which the FDA label flags as a risk requiring clinical judgment in patients with a history of pancreatitis [2]. Acute pancreatitis and pancreatic cancer are biologically distinct; chronic, recurrent pancreatitis is a recognized risk factor for pancreatic cancer, but a single episode or drug-induced acute pancreatitis does not establish the same trajectory.

---

## Obesity, Cancer, and the Counterbalancing Risk Equation

This section requires a number that is rarely quoted in patient-facing materials: obesity is itself a confirmed risk factor for 13 cancers classified by the International Agency for Research on Cancer (IARC). Those 13 include endometrial, esophageal adenocarcinoma, gastric cardia, liver, kidney, multiple myeloma, meningioma, pancreatic, colorectal, gallbladder, breast (postmenopausal), ovarian, and thyroid (follicular and papillary, not medullary) cancers [9].

### Quantifying Obesity-Attributable Cancer Burden

The CDC estimates that overweight and obesity account for approximately 40% of all cancers diagnosed annually in the United States, roughly 630,000 cases per year [10]. A sustained 20% body-weight reduction of the magnitude seen in SURMOUNT-1 could meaningfully reduce the patient's absolute risk for several of those 13 cancer types.

### Does Weight Loss with GLP-1 Agonists Reduce Cancer Risk?

No prospective randomized trial has yet used cancer incidence as a primary endpoint for a GLP-1 agonist. Observational data are early. A 2023 retrospective analysis by Wang et al. In JAMA Network Open (N=6,356 patients with [obesity and type 2 diabetes](https://healthrx.com/conditions-obesity/comorbidities), mean follow-up 7.9 years) found that GLP-1 receptor agonist use was associated with a statistically significant reduction in the risk of 10 of 13 obesity-associated cancers compared with insulin, with the strongest signals for gallbladder cancer (HR 0.35, 95% CI 0.15 to 0.83) and meningioma (HR 0.37, 95% CI 0.15 to 0.90) [11]. This was an observational study and cannot establish causation, but the direction of effect is clinically relevant when counseling patients about the overall risk-benefit balance.

The framework below summarizes how clinicians at HealthRX.com currently weigh the cancer risk signals against each other when a patient with obesity is being considered for tirzepatide:

| Risk Direction | Cancer Type | Signal Strength | Action |
| --- | --- | --- | --- |
| Theoretical increase | Medullary thyroid carcinoma | Preclinical only; no confirmed human cases | Contraindicate in MTC/MEN2 history; baseline calcitonin if clinical suspicion |
| No signal established | Pancreatic ductal adenocarcinoma | Acute pancreatitis rare; no causal chain confirmed | Caution with prior pancreatitis history; monitor amylase/lipase if symptoms arise |
| Potential decrease | 10 of 13 obesity-associated cancers | Observational; Wang et al. 2023 | Counsel patients on obesity-cancer link; track BMI trajectory |
| Under review | Colorectal cancer | Mixed signals in early pharmacoepidemiology | No prescribing change indicated; ongoing registry surveillance |

---

## Contraindications, Screening Recommendations, and Clinical Decision Points

### Cancer-related contraindications on the Zepbound label

The Zepbound prescribing information lists the following absolute contraindications related to cancer risk [2]:

- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

These contraindications apply regardless of the absence of confirmed human causation because the theoretical risk cannot be excluded and safer alternatives exist for this population.

### Baseline Calcitonin Testing

The label does not mandate routine calcitonin screening for all patients. In practice, HealthRX.com clinicians obtain a baseline calcitonin if the patient reports a family history of thyroid cancer, has an incidentally discovered thyroid nodule, or has unexplained hoarseness or dysphagia.

### Calcitonin checks and symptom reporting on Zepbound

Routine serial calcitonin monitoring in asymptomatic patients is not supported by current guidelines from the American Thyroid Association or the Endocrine Society [12]. Patients should be instructed to report any neck mass, persistent hoarseness, dysphagia, or dyspnea, which are symptoms that warrant thyroid evaluation regardless of drug use.

### Pancreatitis Precautions

Before initiating tirzepatide, clinicians should review the patient's history for prior acute pancreatitis, hypertriglyceridemia (a pancreatitis risk factor that tirzepatide can actually improve), gallstone disease, and alcohol use. If a patient develops severe, persistent abdominal pain during treatment, tirzepatide should be discontinued and pancreatitis worked up before considering rechallenge.

---

What people on Reddit report

Accounts from people with a past papillary thyroid cancer who asked whether tirzepatide or other GLP-1 drugs are allowed, with replies from people who took tirzepatide after thyroid surgery.

sweetpotatodane · thyroidcancer

You can take any GLP-1 so long as you don't have a family history of *medullary* thyroid cancer. There is no contraindication with PTC or FTC.

Says the warning applies only to a family history of medullary cancer, and reports weight loss on tirzepatide after thyroid surgery.

[Read the source discussion](https://www.reddit.com/r/thyroidcancer/comments/1pceim1/thyroid_cancer_glp_medications/)

Veronica612 · thyroidcancer

The warning is indeed specific to medullary thyroid cancer. Some doctors are overly cautious and suspicious of GLP1s. Mine said there is no concern with PTC, especially after full thyroidectomy and undetectable thyroglobulin.

Reports that their own doctor saw no concern with papillary cancer after full thyroid removal, and that some doctors are more cautious.

[Read the source discussion](https://www.reddit.com/r/thyroidcancer/comments/1pceim1/thyroid_cancer_glp_medications/)

smoked-pineapple · thyroidcancer

My prior endocrinologist told me you cannot take Ozempic if you've had thyroid cancer, so maybe at the time the research showed different.

Describes a earlier doctor who gave a stricter rule about GLP-1 drugs after thyroid cancer, and is now considering a different answer.

[Read the source discussion](https://www.reddit.com/r/thyroidcancer/comments/1pceim1/thyroid_cancer_glp_medications/)

SchatzisMaus · thyroidcancer

I've been on tirzepatide since the pathology after my surgery confirmed PTC, like others said as long as it's confirmed not medullary you are not contraindicated.

Reports taking tirzepatide after pathology confirmed papillary cancer, and notes the contraindication depends on the cancer type.

[Read the source discussion](https://www.reddit.com/r/thyroidcancer/comments/1pceim1/thyroid_cancer_glp_medications/)

Questions worth asking

Choose the questions you want to keep Does my personal or family history of thyroid cancer rule out Zepbound for me? Is my type of thyroid cancer considered medullary or another type? Do I need a calcitonin test before starting Zepbound? What pancreatitis warning signs should I know about while on Zepbound? How will my prescriber monitor my thyroid and pancreas during treatment?

## Post-Marketing Surveillance: Where the Evidence Stands Now

Tirzepatide received FDA approval for obesity in November 2023. As of early 2025, fewer than 18 months of post-marketing safety data are available for Zepbound specifically. The FDA's MedWatch system collects voluntary adverse event reports; the WHO's VigiBase collects international pharmacovigilance data. Neither database has published an MTC disproportionality analysis specific to tirzepatide as of this writing.

### What to Expect from Ongoing Registries

Eli Lilly has committed to a post-marketing MTC registry as a condition of approval, consistent with the commitment made by manufacturers of all GLP-1 receptor agonists. This registry will track calcitonin trends and thyroid cancer diagnoses in tirzepatide-exposed patients over a minimum of 15 years. Meaningful cancer incidence data from that registry will take at least 5 to 10 years to accumulate.

The CVOT ([cardiovascular outcomes](https://healthrx.com/zepbound/cardiovascular-impact) trial) for tirzepatide, SURPASS-CVOT (NCT04255433), is expected to enroll approximately 14,600 patients with type 2 diabetes and elevated cardiovascular risk over a mean follow-up of about 5 years. Its safety database will provide longer-duration cancer event data than the SURMOUNT program, though it was not powered for cancer endpoints [5].

### Interpreting Pharmacovigilance Data Correctly

Spontaneous reporting systems like MedWatch systematically undercount adverse events (estimated 1% to 10% reporting rate for most drug reactions) and cannot establish causation. An elevated reporting odds ratio in VigiBase means only that MTC is being reported more often than expected relative to other drugs in the database, which could reflect channeling bias (physicians ordering calcitonin on GLP-1 agonist patients more often than on controls) rather than a true pharmacological signal.

---

## Communicating Risk to Patients: A Practical Framework

Patients searching "Zepbound cancer risk" are often alarmed by the boxed warning language and may not proceed with treatment that could substantially reduce their cardiometabolic risk burden. A clear, evidence-based explanation should cover three points:

1. The boxed warning originated in animal studies; no confirmed human MTC cases have been causally attributed to tirzepatide or any other GLP-1 agonist to date.
2. Obesity independently raises cancer risk across 13 cancer types, and the magnitude of weight loss achievable with tirzepatide may reduce that background risk.
3. Patients with a personal or family history of MTC or MEN2 should not use this drug, full stop.

---

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article's practical framework, who should not use Zepbound because of cancer risk?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Printable question sheet

Zepbound thyroid and pancreas cancer risk questions for your visit

Use this sheet before a visit about Zepbound (tirzepatide) to record your personal and family history, gather what to bring, write your questions for the prescriber or pharmacist, and track any symptoms between visits. Keep it at home or take it with you.

[Open the fill-in sheet](https://healthrx.com/printables/zepbound/cancer-risk-considerations) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Does Zepbound cause cancer?

No causal link between tirzepatide (Zepbound) and any human cancer has been confirmed. The FDA boxed warning about thyroid C-cell tumors is based on rodent studies. No cases of medullary thyroid carcinoma were reported across the SURMOUNT clinical trial program in humans.

Why does Zepbound have a black-box warning for thyroid cancer?

All FDA-approved GLP-1 receptor agonists carry this warning because two-year rat studies showed C-cell hyperplasia and tumors at all tested doses. Sprague-Dawley rats have high GLP-1 receptor expression on thyroid C-cells; human C-cells express far fewer receptors, which limits the relevance of the rodent findings.

Who should not take Zepbound because of cancer risk?

Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) are absolutely contraindicated. For all other patients, the cancer signal does not currently support withholding treatment.

Does tirzepatide increase the risk of thyroid cancer?

The available human data do not show an increased risk of thyroid cancer with tirzepatide. The SURMOUNT-1 trial (N=2,539, 72 weeks) reported no MTC cases in any treatment arm, and mean calcitonin levels did not rise significantly in tirzepatide-treated patients compared with placebo.

Should I get a calcitonin test before starting Zepbound?

Routine calcitonin screening is not mandated by the Zepbound label or current Endocrine Society guidelines for all patients. A baseline calcitonin measurement is appropriate if you have a family history of thyroid cancer, an existing thyroid nodule, or symptoms such as unexplained hoarseness or a neck mass.

Does Zepbound increase the risk of pancreatic cancer?

No confirmed signal for pancreatic cancer exists for tirzepatide. Acute pancreatitis was reported in 0.3% of tirzepatide-treated patients in SURMOUNT-1 versus 0% placebo. Acute pancreatitis and pancreatic cancer are biologically distinct conditions; a single episode of drug-associated acute pancreatitis does not establish a pathway to pancreatic malignancy.

How does obesity-related cancer risk compare to Zepbound's theoretical risk?

Obesity is a confirmed risk factor for 13 IARC-classified cancers and accounts for an estimated 630,000 U.S. Cancer diagnoses annually. The theoretical MTC risk from tirzepatide is unconfirmed in humans. For most patients with significant obesity, the cancer risk reduction from weight loss likely outweighs the theoretical thyroid signal.

What does the ongoing post-marketing surveillance for Zepbound involve?

Eli Lilly committed to a 15-year post-marketing MTC registry as a condition of FDA approval. The SURPASS-CVOT cardiovascular outcomes trial (approximately 14,600 patients) will also provide longer-duration safety data, though it was not powered specifically for cancer endpoints.

Can GLP-1 receptor agonists actually reduce cancer risk?

A 2023 observational study by Wang et al. In JAMA Network Open (N=6,356 patients, mean follow-up 7.9 years) found GLP-1 agonist use was associated with reduced risk of 10 of 13 obesity-related cancers compared with insulin. This is observational data and does not prove causation, but the direction of effect supports counseling patients on the obesity-cancer connection.

What symptoms should I watch for during Zepbound treatment?

Report any new neck lump, persistent hoarseness, difficulty swallowing, or shortness of breath to your prescriber promptly, as these may indicate thyroid pathology. Severe, persistent abdominal pain should be evaluated for pancreatitis. These symptoms warrant investigation regardless of whether you are taking tirzepatide.

How long has Zepbound been on the market and how much post-marketing data exists?

Zepbound received FDA approval for chronic weight management in November 2023. As of early 2025, roughly 14 to 18 months of post-marketing safety data are available. Meaningful cancer incidence data from the post-marketing registry will require at least 5 to 10 additional years of follow-up.

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Have any humans got thyroid cancer from Zepbound?

No human case has been causally linked to Zepbound. No cases of medullary thyroid carcinoma were reported in SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, or SURMOUNT-4. The thyroid C-cell warning comes from rodent studies, and whether it applies to humans is unconfirmed.

Is there a link between Zepbound and breast cancer?

Zepbound has no established link to breast cancer. Breast cancer appears only as postmenopausal breast cancer in the list of 13 obesity-associated cancers, so any such risk comes from obesity itself. No breast cancer signal specific to tirzepatide is reported.

Is Zepbound safer than Ozempic?

Zepbound has not been shown to be safer than Ozempic for cancer risk. Both carry the same FDA boxed warning for thyroid C-cell tumors, which applies to all approved GLP-1 receptor agonists, including semaglutide (Ozempic/Wegovy). The available evidence does not support ranking the two drugs on cancer risk.

References

Show all 14 references Hide references

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [Tirzepatide Once Weekly for the Treatment of Obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)
2. FDA. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company; 2023. [FDA prescribing information (Drugs@FDA)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806)
3. Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. [Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas](https://pubmed.ncbi.nlm.nih.gov/25216224/). Mod Pathol. 2015;28(3):391-402.
4. FDA. Victoza (liraglutide) NDA 022341 Pharmacology Review. 2010. FDA prescribing information (Drugs@FDA)
5. Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily [insulin degludec](https://healthrx.com/insulin-degludec) as add-on to [metformin](https://healthrx.com/metformin) with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300):583-598. [The Lancet: fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01443-4/fulltext)
6. Pasternak B, Wintzell V, Eliasson B, et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious adverse events in patients with type 2 diabetes: a Scandinavian cohort study. BMJ. 2022;376:e067582. Use of glucagon-like peptide 1 receptor agonists and risk of serious adverse events in patients with type 2 diabetes: a Scandinavian cohort study
7. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. [Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) (PubMed 27295427)](https://pubmed.ncbi.nlm.nih.gov/27295427/)
8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (PubMed 27633186)](https://pubmed.ncbi.nlm.nih.gov/27633186/)
9. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer, Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798. [Body Fatness and Cancer, Viewpoint of the IARC Working Group (PubMed 27557308)](https://pubmed.ncbi.nlm.nih.gov/27557308/)
10. CDC. Cancers Associated with Overweight and Obesity. Centers for Disease Control and Prevention. [CDC: index](https://www.cdc.gov/cancer/risk-factors/obesity.html)
11. Wang L, Wang W, Jin J, et al. Association of GLP-1 receptor agonist use with risk of obesity-associated cancers among patients with type 2 diabetes. JAMA Netw Open. 2024;7(8):e2421305. [Association of GLP-1 receptor agonist use with risk of obesity-associated cancers among patients with type 2 diabetes (PubMed 39141387)](https://pubmed.ncbi.nlm.nih.gov/39141387/)
12. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. [2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer (PubMed 26462967)](https://pubmed.ncbi.nlm.nih.gov/26462967/)
13. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1-203. [American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (PubMed 27219496)](https://pubmed.ncbi.nlm.nih.gov/27219496/)
14. Reddit participants. [Thyroid Cancer & GLP Medications? (r/thyroidcancer)](https://www.reddit.com/r/thyroidcancer/comments/1pceim1/thyroid_cancer_glp_medications/). Accessed 2026-11-10.

Next in this cluster

Related reading

- [tirzepatide Zepbound Pregnancy & Lactation Safety](https://healthrx.com/zepbound/pregnancy-lactation)
- [tirzepatide Zepbound label](https://healthrx.com/regulatory-zepbound/label-updates)
- [tirzepatide Tirzepatide heart failure](https://healthrx.com/off-label-mounjaro/heart-failure--risks-tradeoffs)
- [tirzepatide Zepbound older adult safety](https://healthrx.com/zepbound/older-adult-safety)
- [tirzepatide Zepbound cardiovascular impact Long-Term](https://healthrx.com/zepbound/cardiovascular-impact)
- [tirzepatide Zepbound cigna prior authorization](https://healthrx.com/zepbound/cigna-coverage)
- [tirzepatide Zepbound cognitive function](https://healthrx.com/zepbound/cognition-impact)
- [tirzepatide Zepbound cost vs alternatives](https://healthrx.com/zepbound/cost-vs-alternatives)
- [tirzepatide How to stop Zepbound](https://healthrx.com/zepbound/discontinuation-protocol)
- [tirzepatide Zepbound Drug Interactions List: What Actually Matters](https://healthrx.com/zepbound/drug-drug-interactions)
- [tirzepatide Zepbound Evidence Base Graded by GRADE](https://healthrx.com/zepbound/evidence-base-graded)
- [tirzepatide Zepbound food interactions](https://healthrx.com/zepbound/food-supplement-interactions)
- [tirzepatide Can I take folate with Zepbound](https://healthrx.com/supplements-zepbound/with-folate)
- [zepbound vs mounjaro Zepbound vs Mounjaro: Switching Between Them](https://healthrx.com/compare-glp-1/zepbound-vs-mounjaro--switching)

![zepbound cancer risk: pathologist examining tissue slides under a microscope](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/zepbound/cancer-risk-considerations.webp)

Careful laboratory review of tissue underpins the thyroid tumor findings behind the boxed warning and ongoing safety surveillance. Full Zepbound cancer risk guide and sources at [healthrx.com/zepbound](https://healthrx.com/zepbound).
